AU2015296142A1 - Dry powder formulations for inhalation - Google Patents

Dry powder formulations for inhalation Download PDF

Info

Publication number
AU2015296142A1
AU2015296142A1 AU2015296142A AU2015296142A AU2015296142A1 AU 2015296142 A1 AU2015296142 A1 AU 2015296142A1 AU 2015296142 A AU2015296142 A AU 2015296142A AU 2015296142 A AU2015296142 A AU 2015296142A AU 2015296142 A1 AU2015296142 A1 AU 2015296142A1
Authority
AU
Australia
Prior art keywords
particles
acetylsalicylic acid
composition
dry
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015296142A
Other languages
English (en)
Inventor
Kambiz Yadidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otitopic Inc
Original Assignee
Otitopic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55218356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015296142(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otitopic Inc filed Critical Otitopic Inc
Publication of AU2015296142A1 publication Critical patent/AU2015296142A1/en
Priority to AU2020203437A priority Critical patent/AU2020203437B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015296142A 2014-07-31 2015-07-31 Dry powder formulations for inhalation Abandoned AU2015296142A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203437A AU2020203437B2 (en) 2014-07-31 2020-05-26 Dry powder formulations for inhalation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031811P 2014-07-31 2014-07-31
US62/031,811 2014-07-31
PCT/US2015/043128 WO2016019253A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203437A Division AU2020203437B2 (en) 2014-07-31 2020-05-26 Dry powder formulations for inhalation

Publications (1)

Publication Number Publication Date
AU2015296142A1 true AU2015296142A1 (en) 2017-02-23

Family

ID=55218356

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015296142A Abandoned AU2015296142A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation
AU2020203437A Active AU2020203437B2 (en) 2014-07-31 2020-05-26 Dry powder formulations for inhalation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203437A Active AU2020203437B2 (en) 2014-07-31 2020-05-26 Dry powder formulations for inhalation

Country Status (10)

Country Link
EP (2) EP4218734A1 (enExample)
JP (1) JP6850524B2 (enExample)
KR (2) KR102603897B1 (enExample)
CN (2) CN116687887A (enExample)
AU (2) AU2015296142A1 (enExample)
CA (1) CA2991760C (enExample)
DK (1) DK3179986T3 (enExample)
ES (1) ES2942297T3 (enExample)
PL (1) PL3179986T3 (enExample)
WO (1) WO2016019253A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
US10568894B2 (en) 2016-06-03 2020-02-25 Otitopic Inc. Dry powder formulations for inhalation
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019059953A2 (en) * 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
EP4311566A1 (en) 2022-07-28 2024-01-31 Vectura Inc. An inhaler comprising a retention element

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
WO1996032096A1 (en) 1995-04-14 1996-10-17 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
EE04004B1 (et) 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JP2001517692A (ja) 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1913939T (pt) * 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
PT1455755E (pt) 2001-11-20 2013-06-18 Civitas Therapeutics Inc Composições particuladas melhoradas para distribuição pulmonar
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20080044481A1 (en) 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
NZ561649A (en) 2005-03-28 2011-02-25 Pericor Therapeutics Inc Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
US8614255B2 (en) 2007-08-21 2013-12-24 Civitas Therapeutics, Inc. Pulmonary pharmaceutical formulations
WO2009103035A2 (en) 2008-02-13 2009-08-20 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
CN104703584B (zh) 2012-02-28 2019-05-31 艾塞尤提卡控股公司 可吸入药物组合物
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HK1218855A1 (zh) * 2013-04-30 2017-03-17 Otitopic Inc. 干粉製劑及使用方法
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation

Also Published As

Publication number Publication date
WO2016019253A1 (en) 2016-02-04
ES2942297T3 (es) 2023-05-31
EP4218734A1 (en) 2023-08-02
CN107072947A (zh) 2017-08-18
JP6850524B2 (ja) 2021-03-31
CN116687887A (zh) 2023-09-05
AU2020203437B2 (en) 2020-09-17
WO2016019253A9 (en) 2016-05-12
KR20170039255A (ko) 2017-04-10
EP3179986A4 (en) 2018-02-07
EP3179986B1 (en) 2023-03-15
AU2020203437A1 (en) 2020-06-11
CA2991760A1 (en) 2016-02-04
KR102603897B1 (ko) 2023-11-20
PL3179986T3 (pl) 2023-06-26
KR102666667B1 (ko) 2024-05-17
CA2991760C (en) 2025-05-06
DK3179986T3 (da) 2023-05-01
JP2017523189A (ja) 2017-08-17
EP3179986A1 (en) 2017-06-21
KR20230119032A (ko) 2023-08-14

Similar Documents

Publication Publication Date Title
US9993488B2 (en) Dry powder formulations for inhalation
US11819569B2 (en) Treating inflammation with inhaled aspirin
AU2020203437B2 (en) Dry powder formulations for inhalation
US12343425B2 (en) Dry powder formulations for inhalation
US12144820B2 (en) Dry powder formulations for inhalation
HK1240081B (en) Dry powder formulations for inhalation
HK1240081A1 (en) Dry powder formulations for inhalation
HK1232442A1 (en) Dry powder formulations for inhalation
HK1232442B (en) Dry powder formulations for inhalation

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted